comparemela.com

Latest Breaking News On - Data monitoring safety board - Page 1 : comparemela.com

Transcripts For CNN New Day With Alisyn Camerota and John Berman

determine whether its coronavirus vaccine is safe for infants and young children. this is so important. it s important for school. it s important for getting and keeping the country back to normal. the first participants have already been vaccinated. the plan is to ultimately enroll nearly 7,000 children in the u.s. and canada between the ages of 6 months and 11 years old. also the white house drawing up plans to increase the supply of vaccines to emerging hot spots. the vaccination rate in the u.s. is accelerating. now standing at an average 26.4 million shots reported a day. president biden meantime heading to pennsylvania. a bit later. his first stop on the help is here tour where he ll promote the benefits of the coronavirus b relief bill. let s bring in dr. sanjay gupta. obviously, very important because when we talk about getting everyone, all adult americans vaccinated by may 1st or july 1st, we re not even beginning to talk about kids yet. that s why this trial ma

Statin lowers cardiovascular disease risk in people with HIV: study

Study findings presented this week at a major HIV conference show that taking a statin every day substantially reduces the chances of suffering a major adverse cardiovascular event in people living with HIV who have a low to moderate risk of cardiovascular disease. The findings were also publis.

Anavex Life Sciences (AVXL) Q2 2021 Earnings Call Transcript

Christopher Missling [Audio gap] the quest for disease-confined therapies for neurodegenerative disorders. Separately, the independent Data Monitoring Safety Board, DSMB, also like the ongoing clinical trial program, including the late-stage AVATAR RS-002, EXCELLENCE RS-003, and the US Rett syndrome extension study, RS-EP-001 of Anavex 2-73 has also completed its recent pre-planned review of the respective interim safety data for these three separate clinical studies. Upon review of the interim safety data, the DSMB made the following recommendation for each of the three studies. The DSMB recommendation is to continue the studies without modifications. This is very good news and indicates we re on the right path with all these studies. As a reminder, our clinical strategy is to clearly differentiate from other biopharma companies and clinical studies in CNS. Anavex is continuing to pioneer the approach of big data, including Anavex in clinical trials to leverage the level of phenot

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.